NIS to examine disease activity in SLE patients treated with subcutaneous anifrolumab in routine care

Trial Identifier: D3461R00100
Sponsor: AstraZeneca
Collaborator:
None
Start Date: March 2026
Primary Completion Date: August 2029
Study Completion Date: August 2029
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Germany Altenburg, Germany
Germany Bad Bramstedt, Germany
Germany Berlin, Germany
Germany Chemnitz, Germany
Germany Erlangen, Germany
Germany Heidelberg, Germany
Germany Herne, Germany
Germany Kassel, Germany
Germany Leipzig, Germany
Germany Meerbusch-Lank, Germany
Germany Muenchen, Germany
Germany Planegg, Germany
Germany Schwerin, Germany
Germany Trier, Germany
Germany Wetzlar, Germany
Germany Wuppertal, Germany